

Special Issue

Vaccines in Farm Animals

Message from the Guest Editors

In this special issue we focus on the development, characterization, field trials and efficiency tests of vaccines aimed at stopping or preventing diseases affecting animals and humans, with an especial interest in those related to livestock. To this end, we invite you to submit an original research or review to this Special Issue covering (but not limited to) the following topics: a) Vaccines against protozoan parasites (e.g. *Toxoplasma*, *Neospora*, *Eimeria*, *Theileria*, *Tritrichomonas*...) b) Vaccines against diseases affecting ruminants, with especial interest in those vertically transmitted or causing abortion (protozoans, viruses, bacteria...) c) Vaccines against diseases transmitted to humans through animal products (meat, milk, eggs...) d) Recombinant or inactivated vaccine trials in livestock (cattle, sheep, goat, poultry, pigs...) e) Vaccines based on genetically modified organisms affecting animals and humans (knockout, exogenous expression of heterologous proteins/antigens) We are looking forward to your interesting manuscript and do not hesitate to contact us should you require further information.

Guest Editors

Dr. David Arranz-Solís

Dr. Yanina Paola Hecker

Dr. Valentin Pérez

Deadline for manuscript submissions

closed (31 July 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/88544

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).